Table 2 US FDA-approved targeted therapies for ovarian cancer
From: Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?
Drug class | Ovarian cancer indication | Black box warnings | Warnings and precautions | |
|---|---|---|---|---|
Bevacizumab [33] | VEGF inhibitor; anti-angiogenesis | Platinum-resistant recurrent disease • In combination with paclitaxel, PLD, or topotecan with no more than 2 prior lines of chemotherapy Platinum-sensitive recurrent disease • In combination with carboplatin and paclitaxel, or carboplatin and gemcitabine; followed by single-agent bevacizumab | • Gastrointestinal perforations • Surgery and wound healing complications • Hemorrhage | • Perforation or fistula • Arterial and venous thromboembolic events • Hypertension • Posterior reversible encephalopathy syndrome • Proteinuria • Infusion reactions • Embryo-fetal toxicity • Ovarian failure |
Niraparib [36] | PARP inhibitor | Maintenance treatment of recurrent disease in complete or partial response to platinum-based chemotherapy | None | • Myelodysplastic syndrome/acute myeloid leukemia • Bone marrow suppression • Cardiovascular effects (blood pressure and heart rate) • Embryo-fetal toxicity |
Olaparib [35] | PARP inhibitor | Maintenance treatment of recurrent disease in complete or partial response to platinum-based chemotherapy Treatment of deleterious or suspected deleterious germline BRCA-mutated disease with ≥3 prior lines of chemotherapy; requires FDA-approved companion diagnostic test | None | • Myelodysplastic syndrome/acute myeloid leukemia • Pneumonitis • Embryo-fetal toxicity |
Rucaparib [34] | PARP inhibitor | Monotherapy in patients with deleterious BRCA mutations treated with two or more prior chemotherapies; requires companion diagnostic test | None | • Myelodysplastic syndrome/acute myeloid leukemia • Embryo-fetal toxicity |